NEW YORK, Sept. 30, 2011 (GLOBE NEWSWIRE) -- Veteran business journalist Joya Dass joins Thomas B. King, President and Chief Executive Officer, Alexza Pharmaceuticals, Inc. [ALXA] to discuss the company's lead program, technology development strategy, financials and positioning.
Click here to view video: http://investor.shareholder.com/ceosignature/webcast.cfm?mediaid=49437&k=20D18C32C82569FF0992E3EF2BDE959E
Thomas B. King, President and Chief Executive Officer
Thomas B. King has served as Alexza's President, Chief Executive Officer and a member of the Company's Board of Directors since June 2003. From 2002 to 2003, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Cognetix, Inc., a privately-held biopharmaceutical company. From 1994 to 2001, Mr. King held various senior executive positions, including President and Chief Executive Officer, and was a member of the board of directors at Anesta Corporation, a publicly-traded pharmaceutical company, until Anesta was acquired by Cephalon, Inc. in 2000. Mr. King received an M.B.A. from the University of Kansas and a B.A. in chemistry from McPherson College.
About Alexza Pharmaceuticals, Inc. [ALXA]:
Alexza is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)
Adasuve™ (Staccato loxapine), Alexza's lead program, is being developed for the rapid treatment of agitation in adults with schizophrenia or bipolar disorder. Alexza has completed and announced positive results from both of its Phase 3 clinical trials and initially submitted the ADASUVE NDA in December 2009. In October 2010, the Company received a Complete Response Letter from the FDA regarding the application. The Company completed an end-of-review meeting with the FDA in December 2010 and a Risk Evaluation and Mitigation Strategy (REMS) guidance meeting with the FDA in April 2011. The ADASUVE NDA was resubmitted on August 4, 2011, and has a Prescription Drug User Fee Act (PDUFA) goal date of February 4, 2012. The FDA has indicated that it will likely present the ADASUVE application to an Advisory Committee during the review period. The Company also plans to file the ADASUVE Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in the second half of 2011.
For more information on the opportunity to have your CEO discuss your company, please call NASDAQ CEO Signature Series, 978/461-3141.
The NASDAQ CEO Signature Series logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4839